UBS Group AG
- SEC CIK
- 0001610520
- Latest filing
- Aug 13, 2026
IKT holding history
Inhibikase Therapeutics, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
IKT overviewAll 13F holders of IKTFull Q2 2026 holdings
- Shares (Q2 2026)
- 204,654
- Value
- $415.4K
- % of portfolio
- <0.1%
- Quarters held
- 15
- Since Q3 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 204,654 | $415.4K | <0.1% | −23,497−10.3% | Reduced | Holders |
| Q1 2026 | 228,151 | $383.3K | <0.1% | +133,606+141.3% | Added | Holders |
| Q4 2025 | 94,545 | $193.8K | <0.1% | −41,735−30.6% | Reduced | Holders |
| Q3 2025 | 136,280 | $220.8K | <0.1% | +97,606+252.4% | Added | Holders |
| Q2 2025 | 38,674 | $75.4K | <0.1% | −6,592−14.6% | Reduced | Holders |
| Q1 2025 | 45,266 | $99.1K | <0.1% | +17,740+64.4% | Added | Holders |
| Q4 2024 | 27,526 | $89.5K | <0.1% | +22,653+464.9% | Added | Holders |
| Q3 2024 | 4,873 | $6.33K | <0.1% | +4,873 | New | Holders |
| Q2 2024 | 0 | $0 | 0.0% | −3,214−100.0% | Sold out | Holders |
| Q1 2024 | 3,214 | $6.94K | <0.1% | +3,214 | New | Holders |
| Q4 2023 | 0 | $0 | 0.0% | −149−100.0% | Sold out | Holders |
| Q3 2023 | 149 | $207 | <0.1% | +149 | New | Holders |
| Q1 2023 | 0 | $0 | 0.0% | −130−100.0% | Sold out | Holders |
| Q4 2022 | 130 | $65 | <0.1% | −7,369−98.3% | Reduced | Holders |
| Q3 2022 | 7,499 | $7.00K | <0.1% | +7,499 | New | Holders |
| Q2 2022 | 0 | $0 | 0.0% | −5,112−100.0% | Sold out | Holders |
| Q1 2022 | 5,112 | $8.00K | <0.1% | +3,353+190.6% | Added | Holders |
| Q4 2021 | 1,759 | $3.00K | <0.1% | −6,789−79.4% | Reduced | Holders |
| Q3 2021 | 8,548 | $16.0K | <0.1% | +8,548 | New | Holders |